Related Experiment Videos

Head and neck cancer antigens recognized by the humoral immune system

Mikio Monji1, Satoru Senju, Tetsuya Nakatsura

  • 1Division of Immunogenetics, Department of Neuroscience and Immunology, Kumamoto University Graduate School of Medical Sciences, 2-2-1 Honjo, Kumamoto, Japan.

Insights

Researchers identified novel human head and neck cancer antigens using the SEREX method. These identified antigens show potential for future cancer diagnosis and immunotherapy development in squamous cell carcinoma of head and neck.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Advanced head and neck cancers present significant treatment challenges.
  • Novel therapeutic strategies and preventive measures are crucial for improving patient outcomes.
  • Understanding the tumor-immune system interaction is key to developing targeted therapies.

Purpose of the Study:

  • To identify novel human head and neck cancer antigens recognized by the humoral immune system.
  • To explore the potential of these antigens as diagnostic markers and therapeutic targets.
  • To investigate the expression patterns of identified antigens in various tissues.

Main Methods:

  • Utilized the Serological Analysis of Recombinant cDNA Expression Libraries (SEREX) approach.
  • Screened cDNA libraries from squamous cell carcinoma of head and neck (SCCHN) and normal testicular tissue using patient sera.
  • Performed reverse transcription-polymerase chain reaction (RT-PCR) for expression analysis on normal and cancer tissues.

Main Results:

  • Identified 28 positive clones corresponding to 19 different genes (12 known, 7 unknown).
  • Eight genes showed ubiquitous expression, while nine were preferentially expressed in cancer tissues.
  • Discovered two cancer/testis antigens with potential clinical relevance.

Conclusions:

  • The identified antigens are promising candidates for head and neck cancer diagnosis.
  • These antigens may serve as targets for future cancer immunotherapy strategies.
  • Further validation is needed to confirm their clinical utility in squamous cell carcinoma of head and neck.

Related Concept Videos